(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.85%.
Celldex Therapeutics's earnings in 2026 is -$300,549,000.On average, 15 Wall Street analysts forecast CLDX's earnings for 2026 to be -$333,522,775, with the lowest CLDX earnings forecast at -$347,854,415, and the highest CLDX earnings forecast at -$305,911,792. On average, 15 Wall Street analysts forecast CLDX's earnings for 2027 to be -$339,498,873, with the lowest CLDX earnings forecast at -$384,716,177, and the highest CLDX earnings forecast at -$268,806,588.
In 2028, CLDX is forecast to generate -$276,902,983 in earnings, with the lowest earnings forecast at -$397,108,137 and the highest earnings forecast at -$106,368,251.